From research to marketability: Zurich offers ideal conditions for successful spin-offs

The founding of a spin-off typically involves a transition from pure research to commercialization, something that presents a considerable challenge. This process involves developing a marketable application or product based on the results of research. It includes aspects such as product development, market analysis, business modeling, financing, legal framework conditions, and setting up a fully operational business. These hurdles need to be cleared in order to turn a scientific idea into a successful commercial enterprise.

Targeted support improves competitiveness

To help close the gap between scientific research and use in practice, University Medicine Zurich (UMZH) is offering interested spin-offs an opportunity to improve their competitiveness with the Translational Medicine Accelerator (TMA). If the development process receives professional support and is therefore accelerated, this can give medical innovations a better chance of succeeding on the market. The TMA offers tailored advice, business courses, and mentoring, and connects company founders with relevant parties from industry and also investors. The UZH Life Sciences Fund is particularly worthy of mention. This provides specific financial support for spin-offs to help them develop their business strategy and successfully scale up their projects.

The TMA has supported almost 100 projects over the past three years. An important role is also played by SPARK ZURICH, a mentoring network supported by the TMA, which is based on the successful program with the same name, run by Stanford University in the USA. Founder teams are able to present their projects and plans and benefit from feedback given by a range of external experts.

Zurich as a unique place for business and commerce

The city itself, as a location, offers ideal conditions for innovative life sciences companies that are looking to build a successful business. And as Switzerland’s business hub, the «Greater Zurich Area» certainly impresses with its high density of small biotech companies, established industry partners, and leading-edge laboratory infrastructure. The region also offers access to the «Swissmedic Innovation Office,» which supports innovations in the area of medical devices and medicines. The promotion of spin-offs not only facilitates the emergence of innovative companies, but also creates highly skilled jobs. The proximity to leading universities and renowned university hospitals is another big draw. The close collaboration with leading global research facilities and access to international markets are of particular interest to investors.
By helping to fuel this dynamic innovation landscape, University Medicine Zurich is making a considerable contribution toward strengthening Zurich’s position as a leading center for medical innovations. This ultimately results in a significant improvement in healthcare provision and emphasizes Zurich’s key role in the global life sciences sector.